There is a Mary Ann Liebert at Mary Ann Liebert, Inc. and that makes a difference.

For Immediate Release

Altered Brain Connectivity May Explain Cognitive Impairment in Pediatric Leukemia Survivors

Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com

Mary Ann Liebert, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com

New Rochelle, NY, May 18, 2016—The neurotoxic effects of chemotherapeutic drugs on the developing brains of young patients with acute lymphoblastic leukemia (ALL) may impair their cognitive functioning by disrupting the formation of neural networks that connect brain regions and transfer information. A study showing reduced connectome organization in the brains of ALL survivors is published in Brain Connectivity, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Brain Connectivity website until June 18, 2016.

Shelli Kesler, PhD, University of Texas MD Anderson Cancer Center, Houston, and coauthors from Stanford University and University of California at San Francisco, used diffusion tensor imaging to analyze and compare the white matter connectome of pediatric ALL survivors and healthy young people. They reported greater cognitive impairment and significantly lower connectivity, based on measures of network clustering and path length, in the ALL group. The researchers describe the study design and present their findings in the article “Atypical Structural Connectome Organization and Cognitive Impairment in Young Survivors of Acute Lymphoblastic Leukemia.”

“As survival rates for cancer patients increase, issues related to survivorship such as chemotherapy-induced cognitive impairment become more important to the cancer research community,” says Christopher Pawela, PhD, Co-Editor-in-Chief of Brain Connectivity and Assistant Professor, Medical College of Wisconsin. “Dr. Kesler and colleagues are developing new MRI-based biomarkers to measure brain changes associated with the neurotoxic effects of chemotherapy in the brain. These biomarkers may find utility in providing insight into the mechanisms of brain damage caused by chemotherapeutic drugs and could be used to develop neuroprotective therapies to mitigate the harmful effects of these drugs on the brain.”

About the Journal
Brain Connectivity is the essential peer-reviewed journal covering groundbreaking findings in the rapidly advancing field of connectivity research at the systems and network levels. Published 10 times per year online with open access options and in print, the Journal is under the leadership of Founding and Co-Editors-in-Chief Christopher Pawela, PhD, Assistant Professor, Medical College of Wisconsin, and Bharat Biswal, PhD, Chair of Biomedical Engineering, New Jersey Institute of Technology. It includes original peer-reviewed papers, review articles, point-counterpoint discussions on controversies in the field, and a product/technology review section. To ensure that scientific findings are rapidly disseminated, articles are published Instant Online within 72 hours of acceptance, with fully typeset, fast-track publication within 4 weeks. Tables of content and a sample issue may be viewed on the Brain Connectivity website.

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative medical and biomedical peer-reviewed journals, including Journal of Neurotrauma and Therapeutic Hypothermia and Temperature Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, newsmagazines, and books is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert 2, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com